Cancer risk associated with DPP4 inhibitors in type 2 diabetes: A pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS).

PLoS One · 2026 · PMC13004328 · PMID 41860942

Europe PMC DOI

hedged sentence

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

did not reach statistical significanceP > 0.05actually significant

Additionally, although the adjusted ROR for saxagliptin was 1.032, indicating a slight increase in the risk of malignancy AEs, this association did not reach statistical significance (P > 0.05), thus precluding a definitive conclusion.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.